TAFI Antibody (13H4): sc-59708
- TAFI Antibody (13H4) is a mouse monoclonal IgG1 TAFI antibody provided at 100 µg/ml
- raised against purified full length native TAFI of human origin
- recommended for detection of TAFI of human origin by WB, IP and ELISA
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for TAFI Antibody (13H4). This work is in progress.
QUICK LINKS
SEE ALSO...
TAFI Antibody (13H4) is a mouse monoclonal IgG1 antibody that detects TAFI protein of human origin by western blotting (WB), immunoprecipitation (IP), and enzyme-linked immunosorbent assay (ELISA). Anti-TAFI antibody (13H4) is available as the non-conjugated format. The Thrombin-activatable fibrinolysis inhibitor (TAFI), also known as procarboxypeptidase B2 or procarboxypeptidase U, plays a crucial role in regulating fibrinolysis, a process essential for maintaining hemostasis and preventing excessive bleeding. Synthesized in the liver and secreted into plasma as an inactive zymogen, TAFI is activated by thrombin, which enables removal of C-terminal arginine or lysine residues from various biologically active peptides, including kinins and anaphylatoxins. This enzymatic activity is significant because TAFI cleaves lysine residues from fibrin, thereby inhibiting plasminogen conversion to plasmin and slowing down fibrin clot dissolution. Elevated TAFI levels in the bloodstream are associated with increased risk of venous thrombosis, while deficiencies can exacerbate bleeding disorders, particularly in hemophilia A and B. Additionally, decreased TAFI levels are often observed in patients with chronic liver disease, highlighting TAFI′s importance in both coagulation and liver function.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
TAFI Antibody (13H4) References:
- Thrombin interacts with thrombomodulin, protein C, and thrombin-activatable fibrinolysis inhibitor via specific and distinct domains. | Hall, SW., et al. 1999. J Biol Chem. 274: 25510-6. PMID: 10464282
- Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. | van Tilburg, NH., et al. 2000. Blood. 95: 2855-9. PMID: 10779431
- Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors. | Juhan-Vague, I., et al. 2000. Arterioscler Thromb Vasc Biol. 20: 2156-61. PMID: 10978263
- Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. | Silveira, A., et al. 2000. Thromb Haemost. 84: 364-8. PMID: 11019956
- Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway. | Bajzar, L. 2000. Arterioscler Thromb Vasc Biol. 20: 2511-8. PMID: 11116046
- Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography. | Schroeder, V., et al. 2002. Thromb Haemost. 88: 1020-5. PMID: 12529754
- Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). | Bouma, BN. and Meijers, JC. 2003. J Thromb Haemost. 1: 1566-74. PMID: 12871292
- Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. | Von dem Borne, PA., et al. 1997. J Clin Invest. 99: 2323-7. PMID: 9153272
- Identification and characterization of two thrombin-activatable fibrinolysis inhibitor isoforms. | Zhao, L., et al. 1998. Thromb Haemost. 80: 949-55. PMID: 9869166
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
TAFI Antibody (13H4) | sc-59708 | 100 µg/ml | $322.00 |